|
1
|
Wild S, Roglic G, Green A, Sicree R and
King H: Global prevalence of diabetes: estimates for the year 2000
and projections for 2030. Diabetes Care. 27:1047–1053.
2004.PubMed/NCBI
|
|
2
|
Tan AL, Forbes JM and Cooper ME: AGE,
RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 27:130–143.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalla Vestra M, Saller A, Bortoloso E,
Mauer M and Fioretto P: Structural involvement in type 1 and type 2
diabetic nephropathy. Diabetes Metab. 26(Suppl 4): 8–14.
2000.PubMed/NCBI
|
|
4
|
American Diabetes Association. Standards
of medical care in diabetes. Diabetes Care. 28(Suppl 1): 4–36.
2005. View Article : Google Scholar
|
|
5
|
Ritz E, Rychlik I, Locatelli F and Halimi
S: End-stage renal failure in type 2 diabetes: a medical
catastrophe of worldwide dimensions. Am J Kidney Dis. 34:795–808.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pugsley MK: The angiotensin-II (AT-II)
receptor blocker olmesartan reduces renal damage in animal models
of hypertension and diabetes. Proc West Pharmacol Soc. 48:35–38.
2005.PubMed/NCBI
|
|
7
|
de Gasparo M, Catt KJ, Inagami T, Wright
JW and Unger T: International union of pharmacology. XXIII. The
angiotensin II receptors. Pharmacol Rev. 52:415–472.
2000.PubMed/NCBI
|
|
8
|
Kohzuki M, Yasujima M, Kanazawa M, et al:
Antihypertensive and renal-protective effects of losartan in
streptozotocin diabetic rats. J Hypertens. 13:97–103. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uehara Y, Hirawa N, Kawabata Y, et al:
Angiotensin II subtype-1 receptor antagonists improve hemodynamic
and renal changes without affecting glucose metabolisms in genetic
rat model of non-insulin-dependent diabetes mellitus. Am J
Hypertens. 12:21–27. 1999. View Article : Google Scholar
|
|
10
|
Yao L, Kobori H, Rahman M, et al:
Olmesartan improves endothelin-induced hypertension and oxidative
stress in rats. Hypertens Res. 27:493–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Adams AJ: Bench to bedside and bedside to
bench: where are we? Optom Vis Sci. 83:125–126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelly A, Li C, Gao Z, Stanley CA and
Matschinsky FM: Glutaminolysis and insulin secretion: from bedside
to bench and back. Diabetes. 51(Suppl 3): 421–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai GL, He JK, Xie Y, Han R, Qin ZH and
Zhu LJ: Therapeutic potential of Naja naja atra venom in a
rat model of diabetic nephropathy. Biomed Environ Sci. 25:630–638.
2012.
|
|
14
|
Yamabe N, Yokozawa T, Oya T and Kim M:
Therapeutic potential of (−)-epigallocatechin 3-O-gallate on renal
damage in diabetic nephropathy model rats. J Pharmacol Exp Ther.
319:228–236. 2006.
|
|
15
|
Ozturk Y, Altan VM and Yildizoglu-Ari N:
Effects of experimental diabetes and insulin on smooth muscle
functions. Pharmacol Rev. 48:69–112. 1996.PubMed/NCBI
|
|
16
|
Junod A, Lambert AE, Orci L, Pictet R,
Gonet AE and Renold AE: Studies of the diabetogenic action of
streptozotocin. Proc Soc Exp Biol Med. 126:201–205. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jones RB, Dickinson K, Anthony DM, Marita
AR, Kaul CL and Buckett WR: Evaluation of BTS 67 582, a novel
antidiabetic agent, in normal and diabetic rats. Br J Pharmacol.
120:1135–1143. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Srinivasan K and Ramarao P: Animal models
in type 2 diabetes research: an overview. Indian J Med Res.
125:451–472. 2007.PubMed/NCBI
|
|
19
|
Kanwar YS, Wada J, Sun L, et al: Diabetic
nephropathy: mechanisms of renal disease progression. Exp Biol Med
(Maywood). 233:4–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakagawa T, Sato W, Glushakova O, et al:
Diabetic endothelial nitric oxide synthase knockout mice develop
advanced diabetic nephropathy. J Am Soc Nephrol. 18:539–550. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ota T, Takamura T, Ando H, Nohara E,
Yamashita H and Kobayashi K: Preventive effect of cerivastatin on
diabetic nephropathy through suppression of glomerular macrophage
recruitment in a rat model. Diabetologia. 46:843–851. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oktem F, Ozguner F, Yilmaz HR, Uz E and
Dundar B: Melatonin reduces urinary excretion of
N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative
markers in diabetic rats. Clin Exp Pharmacol Physiol. 33:95–101.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lewis EJ, Hunsicker LG, Bain RP and Rohde
RD: The effect of angiotensin-converting enzyme inhibition on
diabetic nephropathy. The Collaborative Study Group. N Engl J Med.
329:1456–1462. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Noda M, Matsuo T, Fukuda R, et al: Effect
of candesartan cilexetil (TCV-116) in rats with chronic renal
failure. Kidney Int. 56:898–909. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ueno T, Kaname S, Takaichi K, et al:
LOX-1, an oxidized low-density lipoprotein receptor, was
upregulated in the kidneys of chronic renal failure rats. Hypertens
Res. 26:117–122. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou A, Yu L, Li J, Zhang J and Wang H:
Renal protective effects of blocking the intrarenal
renin-angiotensin system: angiotensin II type I receptor antagonist
compared with angiotensin-converting enzyme inhibitor. Hypertens
Res. 23:391–397. 2000. View Article : Google Scholar
|
|
27
|
Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki
CM and Herman WH: Does microalbuminuria predict diabetic
nephropathy? Diabetes Care. 24:1560–1566. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inada Y, Murakami M, Tazawa S and Akahane
M: KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates
nephropathy and hyperlipidaemia in diabetic spontaneously
hypertensive rats. Clin Exp Pharmacol Physiol. 27:270–276. 2000.
View Article : Google Scholar
|
|
29
|
Baynes JW and Thorpe SR: Role of oxidative
stress in diabetic complications: a new perspective on an old
paradigm. Diabetes. 48:1–9. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fujimoto S, Satoh M, Horike H, et al:
Olmesartan ameliorates progressive glomerular injury in subtotal
nephrectomized rats through suppression of superoxide production.
Hypertens Res. 31:305–313. 2008. View Article : Google Scholar
|
